DSM – Repurchase of Shares (15 – 21 September 2017)

Royal DSM, a global science-based company active in health, nutrition and materials, has repurchased 117,424 of its own shares in the period from 15 September 2017 up to and including 21 September 2017 at an average price of EUR66.56. This is in accordance with the repurchase, covering existing option plans and stock dividends, announced on 14 August 2017. The consideration of this repurchase was EUR7.8 million.

The total number of shares repurchased under this program to date is 862,874 shares for a total consideration of EUR55.8 million.

Advertentie

For more detailed information see the ‘Daily transaction details 1.6m Share Repurchase Program announced 14 Aug 2017 [https://www.dsm.com/corporate/investors/shares/share-buy-back-programs.html]’.

DSM – Bright Science. Brighter Living.(TM)

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about EUR10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com [http://www.dsm.com ].

Advertentie

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

For more information:
DSM Corporate Communications
Stephen Hufton
tel. +31(0)45-5782017
e-mail media.contacts@dsm.com

DSM Investor Relations
Dave Huizing
tel. +31(0)45-5782864
e-mail investor.relations@dsm.com

Source: ANP Pers Support

Photo credit: HealthGauge via Foter.com / CC BY